Savage M P, Fischman D L, Rake R, Leon M B, Schatz R A, Penn I, Nobuyoshi M, Moses J, Hirshfeld J, Heuser R, Baim D, Cleman M, Brinker J, Gebhardt S, Goldberg S
Division of Cardiology, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA.
J Am Coll Cardiol. 1998 Feb;31(2):307-11. doi: 10.1016/s0735-1097(97)00511-1.
The goal of this study was to compare the efficacy of elective stent implantation and balloon angioplasty for new lesions in small coronary arteries.
Palmaz-Schatz stents have been designed and approved by the Food and Drug Administration for use in coronary arteries with diameters > or = 3.0 mm. The efficacy of elective stent placement in smaller vessels has not been determined.
By quantitative coronary angiography, 331 patients in the Stent Restenosis Study (STRESS) I-II were determined to have a reference vessel < 3.0 mm in diameter. Of these, 163 patients were randomly assigned to stenting (mean diameter 2.69 +/- 0.21 mm), and 168 patients were assigned to angioplasty (mean diameter 2.64 +/- 0.24 mm). The primary end point was restenosis, defined as > or = 50% diameter stenosis at 6-month follow-up angiography. Clinical event rates at 1 year were assessed.
Baseline clinical and angiographic characteristics were similar in the two groups. Procedural success was achieved in 100% of patients assigned to stenting and in 92% of patients assigned to angioplasty (p < 0.001). Abrupt closure within 30 days occurred in 3.6% of patients in both groups. Compared with angioplasty, stenting conferred a significantly larger postprocedural lumen diameter (2.26 vs. 1.80 mm, p < 0.001) and a larger lumen at 6 months (1.54 vs. 1.27 mm, p < 0.001). Restenosis (> or = 50% diameter stenosis at follow-up) occurred in 34% of patients assigned to stenting and in 55% of patients assigned to angioplasty (p < 0.001). At 1 year, event-free survival was achieved in 78% of the stent group and in 67% of the angioplasty group (p = 0.019).
These findings suggest that elective stent placement provides superior angiographic and clinical outcomes than balloon angioplasty in vessels slightly smaller than 3 mm.
本研究的目的是比较选择性支架植入术与球囊血管成形术治疗小冠状动脉新病变的疗效。
帕尔马兹-施查茨支架已由美国食品药品监督管理局设计并批准用于直径≥3.0 mm的冠状动脉。选择性支架置入术在较小血管中的疗效尚未确定。
通过定量冠状动脉造影,确定支架再狭窄研究(STRESS)I-II中的331例患者的参考血管直径<3.0 mm。其中,163例患者被随机分配至支架植入组(平均直径2.69±0.21 mm),168例患者被分配至血管成形术组(平均直径2.64±0.24 mm)。主要终点为再狭窄,定义为随访6个月时血管造影显示直径狭窄≥50%。评估1年时的临床事件发生率。
两组患者的基线临床和血管造影特征相似。支架植入组100%的患者和血管成形术组92%的患者手术成功(p<0.001)。两组均有3.6%的患者在30天内发生急性闭塞。与血管成形术相比,支架植入术后即刻管腔直径明显更大(2.26对1.80 mm,p<0.001),6个月时管腔也更大(1.54对1.27 mm,p<0.001)。支架植入组34%的患者和血管成形术组55%的患者发生再狭窄(随访时直径狭窄≥50%)(p<0.001)。1年时,支架组78%的患者和血管成形术组67%的患者无事件生存(p = 0.019)。
这些发现表明,在略小于3 mm的血管中,选择性支架置入术比球囊血管成形术具有更好的血管造影和临床结果。